Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Carcinoma, Non-Small-Cell Lung 47Prostatic Neoplasms 33Breast Neoplasms 23Stomach Neoplasms 16Squamous Cell Carcinoma of Head and Neck 15Lung Neoplasms 15Esophageal Neoplasms 13Neoplasm Metastasis 11Sarcoma 9Neoplasms 9Colorectal Neoplasms 7Urinary Bladder Neoplasms 6Ovarian Neoplasms 6Head and Neck Neoplasms 6Carcinoma, Transitional Cell 6Carcinoma, Renal Cell 6Melanoma 5Uterine Cervical Neoplasms 4Triple Negative Breast Neoplasms 4Small Cell Lung Carcinoma 4Carcinoma, Ovarian Epithelial 4Breast Neoplasms, Male 4Salivary Gland Neoplasms 3Prostatic Neoplasms, Castration-Resistant 3Pancreatic Neoplasms 3Non-Muscle Invasive Bladder Neoplasms 3Leiomyosarcoma 3Inflammatory Breast Neoplasms 3Endometrial Neoplasms 3Carcinoma, Squamous Cell 3

Interventions

Gemcitabine 3Irinotecan 2Albumin-Bound Paclitaxel 2ibrutinib 1adavosertib 1Paclitaxel 1PEGPH20 1Oxaliplatin 1Leucovorin 1Fluorouracil 1Docetaxel 1Cisplatin 1Capecitabine 1130-nm albumin-bound paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Metastatic Pancreatic Adenocarcinoma × Docetaxel × Clear all
NCT02324543 2023-07-21

Study of Gemcitabine/Taxotere/Xeloda (GTX) in Combination With Cisplatin and Irinotecan in Subjects With Metastatic Pancreatic Cancer

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Phase 1/2 Completed
47 enrolled 22 charts
Gastrointestinal

Metastatic Pancreatic Adenocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡